QNTM — Quantum Biopharma Ltd.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1771885 ·
Ontario, Canada
Last close
$7.05
Market Cap
$45.11M
52W High
$10.81
52W Low
$2.07
ADV30
481,604
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -2,909,492 | -13,560,299 | 14,926,075 | 4,341,908 | 16,345,974 |
| Dec 2025 | 0 | — | -2,359,801 | -3,026,467 | 11,160,909 | 1,905,357 | 6,058,294 |
| Sep 2025 | 0 | — | -4,658,195 | -5,319,029 | 14,153,228 | 445,944 | 6,646,480 |
| Jun 2025 | 0 | — | -4,913,790 | -9,253,067 | 15,297,031 | 1,497,576 | 13,249,998 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-8,237,012
Investing CF
$-1,952,469
Financing CF
$6,098,966
CapEx
—
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-12.38
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-198,286,170
Inventory
$52,133
Receivables
$231,053
ST Investments
$459,080
EBIT TTM
$-26,338,200
Pretax Income TTM
$-26,956,840
Interest Exp TTM
$618,640
Analysts
1
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -15,317,409 | -26,175,286 | 11,160,909 | 6,058,294 | — | -8,237,012 |
| Dec 2024 | 0 | -15,884,034 | -14,202,724 | 17,119,224 | 6,678,992 | — | -6,876,479 |
| Dec 2023 | 0 | -19,570,114 | -17,902,179 | 17,474,828 | 4,565,566 | — | -10,827,264 |
| Dec 2022 | 0 | -27,429,611 | -23,606,828 | 38,410,656 | 7,868,436 | — | -28,333,273 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-7.80
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PYRGF | PyroGenesis Canada Inc. | $44.26M | $0.21 | — |
| LTRN | Lantern Pharma Inc. | $43.12M | $3.38 | — |
| VICP | Vicapsys Life Sciences, Inc. | $47.26M | $1.46 | — |
| ATOS | ATOSSA THERAPEUTICS, INC. | $42.63M | $4.95 | — |
| ETST | Earth Science Tech, Inc. | $48.95M | $0.17 | — |
News headlines (Yahoo Finance, 1h cache)
Quantum BioPharma (QNTM) Reports Midpoint Enrollment Milestone in MS Imaging Study
2026-05-19 18:05 · Yahoo
Quantum BioPharma Reaches Halfway Point in Patient Enrollment in Imaging Study With MGH
2026-05-19 11:21 · Yahoo
Quantum BioPharma Shares Climb as Multiple Sclerosis Imaging Study Advances (QNTM)
2026-05-18 14:37 · Yahoo
Quantum BioPharma Reaches Key Midpoint Milestone in Groundbreaking Imaging Study with Massachusetts General Hospital
2026-05-18 07:00 · Yahoo
Quantum Reports Strengthened Liquidity, Reduced Cash Burn, and Disciplined Cost Management in First Quarter 2026
2026-05-07 11:00 · Yahoo
Quantum BioPharma Provides Corporate Update
2026-04-27 23:45 · Yahoo
Quantum BioPharma Licensee Unbuzzd Wellness Inc. Appoints Richard Buzbuzian as CEO to Lead Nationwide Commercialization of Innovative, Clinically Validated Hangover Remedy and Alcohol Metabolism Accel
2026-04-22 13:16 · Yahoo
Quantum BioPharma Wins Significant Court Challenge in USD $700,000,000 Claim as Defendants Joint Motion to Dismiss Lawsuit Alleging Market Manipulation by CIBC World Markets and RBC Dominion Securitie
2026-04-02 12:30 · Yahoo
Quantum BioPharma Submits Investigational New Drug (IND) Application to United States Food and Drug Administration (FDA) for Lucid-MS Phase Two Clinical Trial in Multiple Sclerosis
2026-04-01 12:02 · Yahoo
Quantum BioPharma Signs Binding Letter Of Intent With Allucent To Conduct Phase 2 Clinical Trial In Multiple Sclerosis
2026-03-30 11:50 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.